Compare Ishares Msci Italy ETF (EWI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Twist Bioscience Corp — how do they compare? Ishares Msci Italy ETF trades at $63.25, while Twist Bioscience Corp trades at $124 (market cap $7.82B). Which is the better fit depends on your goals.
| EWI | TWST | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $124.88 |
52-Week Low | $50.31 | $24.16 |
Market Cap | — | $7.82B |
Enterprise Value | — | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, a US-listed stock, trades at $63.35, up 0.3% on the day, with technical indicators showing a bullish moving average trend but overbought oscillators. The stock recently hit a 52-week high, reflecting strong momentum. A dividend of $1.17 is scheduled for payment in June 2026, offering income potential. Recent news highlights European market strength and ECB policy impacts, which may influence EWI's performance given its European exposure.
The outlook for EWI is cautiously optimistic, driven by technical strength and positive European equity trends. Risks include potential ECB rate hikes and geopolitical tensions affecting energy costs. Analyst sentiment is mixed, with the stock near highs suggesting limited upside without new catalysts. Investors should weigh technical overbought signals against fundamental growth prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
